BioPorto A/S

LSE:0JJM Stock Report

Market Cap: DKK 947.4m

BioPorto Management

Management criteria checks 2/4

BioPorto's CEO is Peter Eriksen, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.18% of the company’s shares, worth DKK1.70M. The average tenure of the management team and the board of directors is 0.5 years and 10.5 years respectively.

Key information

Peter Eriksen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.2%
Management average tenureless than a year
Board average tenure10.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Eriksen's remuneration changed compared to BioPorto's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-DKK 54m

Dec 31 2023n/an/a

-DKK 56m

Sep 30 2023n/an/a

-DKK 70m

Jun 30 2023n/an/a

-DKK 78m

Mar 31 2023n/an/a

-DKK 75m

Dec 31 2022DKK 292kn/a

-DKK 76m

Sep 30 2022n/an/a

-DKK 68m

Jun 30 2022n/an/a

-DKK 62m

Mar 31 2022n/an/a

-DKK 59m

Dec 31 2021DKK 3mn/a

-DKK 57m

Sep 30 2021n/an/a

-DKK 54m

Jun 30 2021n/an/a

-DKK 60m

Mar 31 2021n/an/a

-DKK 62m

Dec 31 2020DKK 7mDKK 3m

-DKK 62m

Sep 30 2020n/an/a

-DKK 64m

Jun 30 2020n/an/a

-DKK 68m

Mar 31 2020n/an/a

-DKK 69m

Dec 31 2019DKK 6mDKK 3m

-DKK 70m

Sep 30 2019n/an/a

-DKK 61m

Jun 30 2019n/an/a

-DKK 51m

Mar 31 2019n/an/a

-DKK 43m

Dec 31 2018DKK 4mDKK 3m

-DKK 38m

Sep 30 2018n/an/a

-DKK 38m

Jun 30 2018n/an/a

-DKK 36m

Mar 31 2018n/an/a

-DKK 35m

Dec 31 2017DKK 5mDKK 3m

-DKK 32m

Compensation vs Market: Insufficient data to establish whether Peter's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Eriksen (64 yo)

less than a year

Tenure

DKK 292,000

Compensation

Mr. Peter Mørch Eriksen, BBA, serves as Chief Executive Officer at BioPorto A/S. He served as a Director of BioPorto A/S since November 15, 2021 until April 30, 2024 and served as its Interim CEO from Janu...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Eriksen
Chief Executive Officerless than a yearDKK 292.00k0.18%
DKK 1.7m
Lars Uttenthal
Chief Scientific Officerno datano datano data
Gry Larsen
Executive VP & Chief Legal Officerless than a yearno datano data
Jennifer Zonderman
SVP of Global Marketing & US Commercialization5.2yrsno datano data
Nis Kruse
Executive VP of Strategic Partnerships and GM of EMEA & APAC1.6yrsno datano data
Jeffrey Haas
President & CEO of BioPorto Inc.less than a yearno datano data

0.5yrs

Average Tenure

Experienced Management: 0JJM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Donnie Hardison
Independent Vice Chairman of the Board3.3yrsDKK 795.00k0.0046%
DKK 44.1k
John McDonough
Independent Chairman of the Board3.3yrsDKK 1.08m0.095%
DKK 899.1k
Claudio Ronco
Member of Scientific Advisory Board10.5yrsno datano data
Mats Thoren
Directorno datano datano data
Jean-Louis Vincent
Chairman of the Scientific Advisory Board10.5yrsno datano data
Henrik Juuel
Directorno datano datano data
Ninfa Saunders
Independent Director1.3yrsDKK 458.00kno data
Michael Singer
Independent Director4.9yrsDKK 674.00kno data
Andrew Lewington
Vice Chairman of Scientific Advisory Board10.5yrsno datano data
Laurent Jacob
Member of Scientific Advisory Board10.5yrsno datano data
Michael Haase
Member of Scientific Advisory Board10.5yrsno datano data
Hilde Geus
Member of Scientific Advisory Board10.5yrsno datano data

10.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 0JJM's board of directors are seasoned and experienced ( 10.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/20 05:26
End of Day Share Price 2024/04/22 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioPorto A/S is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Jyoti PrakashEdison Investment Research
Yi ChenH.C. Wainwright & Co.